The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Cisplatin-Associated Nephrotoxicity and Pathological Events
Abstract
Cisplatin (cis-diamminedichloroplatinum(II)) is an effective chemotherapeutic agent, and is successfully used in the treatment of a wide range of tumors. Despite its effectiveness as an anti-tumor drug, nephrotoxic side effects have significantly restricted its clinical use. Tubular epithelial cell deletion following cisplatin treatment is a major cause of renal injury. Oxidative stress significantly contributes to cisplatin-associated cytotoxicity, and use of antioxidants could counteract such cytotoxic effects of cisplatin. The renal microenvironmental changes following cisplatin treatment is a complex process and could be broadly categorized into three main pathological events, which at times might overlap: initial cytotoxic events, inflammatory events and fibroproliferative events. Stress responses and heat shock proteins generated following cisplatin treatment are actively involved in the initiation and progression of these events. In this article, we will briefly summarize factors involved in various phases of cisplatin-induced renal injuries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Fulda, S., Sieverts, H., Friesen, C., Herr, I., & Debatin, K. (1997) · PubMed · Cited by 482
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells
Lieberthal, W., Menza, S. A., & Levine, J. S. (1998) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1998.274.2.f315 · Cited by 377
Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis
Shiraishi, F., Curtis, L. M., Truong, L., Poss, K., Visner, G. A., Madsen, K., Nick, H. S., & Agarwal, A. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.278.5.f726 · Cited by 315
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure
Ramesh, G., & Reeves, W. B. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00101.2003 · Cited by 282
Cited by
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Dietrich, J., Han, R., Yang, Y., Mayer-Pröschel, M., & Noble, M. (2006) · Journal of Biology · doi:10.1186/jbiol50 · Cited by 500
Risk Prediction of Contrast-Induced Nephropathy
McCullough, P. A., Adam, A., Becker, C. R., Davidson, C., Lameire, N., Stacul, F., & Tumlin, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.022 · Cited by 457
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Drug-associated renal dysfunction and injury
Choudhury, D., & Ahmed, Z. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0076 · Cited by 345
Ali, B. H., & Al Moundhri, M. S. (2006) · Food and Chemical Toxicology · doi:10.1016/j.fct.2006.01.013 · Cited by 328
Block, K. I., Koch, A. C., Mead, M. N., Tothy, P. K., Newman, R. A., & Gyllenhaal, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23754 · Cited by 328
Acute nephrotoxicity of cisplatin: Molecular mechanisms
Peres, L. A. B., & Cunha Júnior, A. D. D. (2013) · Jornal Brasileiro de Nefrologia · doi:10.5935/0101-2800.20130052 · Cited by 261
Long–Term Renal Outcomes after Cisplatin Treatment
Latcha, S., Jaimes, E. A., Patil, S., Glezerman, I. G., Mehta, S., & Flombaum, C. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08070715 · Cited by 256
Yousef, M. I., & Hussien, H. M. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.01.014 · Cited by 104
“The clinical usage of cisplatin is limited by its undesirable side effects, including nephrotoxicity, hepatotoxicity, neurotoxicity, ototoxicity, gastrotoxicity, myelosuppression, hair loss, allergic reactions, nausea, and vomiting (Taguchi et al., 2005; Cepeda et al., 2007).”
BackgroundNutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Metadata
- Authors
- Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S.
- Venue
- Contributions to Nephrology
- Publisher
- KARGER
- Published
- 2005
- Volume
- 148
- Pages
- 107-121
- OpenAlex
- W2099252920
- Cited by
- 256
- References
- 53
- FWCI
- 58.07
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.